Tirzepatide

Q: What makes tirzepatide different from semaglutide?

Tirzepatide targets two incretin receptors (GIP and GLP-1) simultaneously, whereas semaglutide exclusively targets GLP-1 receptors. This dual mechanism is the key distinction in research models.

Q: What does GIP stand for?

GIP stands for glucose-dependent insulinotropic polypeptide (also called gastric inhibitory polypeptide). It is an incretin hormone released by K-cells in the small intestine.

Q: Is tirzepatide a high-demand research compound?

Yes. Tirzepatide became one of the most searched research peptides as its mechanisms gained widespread attention in metabolic research literature.

Tirzepatide

Tirzepatide (GIP/GLP-1 Dual Agonist)

Research Use Only · Not for Human Consumption

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual mechanism makes it a unique research tool for studying the combined effects of both incretin pathways on metabolic outcomes. Tirzepatide contains a fatty acid modification that extends its half-life.

Key Facts

Amino acid count: 39
Receptor targets: GIP and GLP-1 receptors
Type: Dual incretin mimetic
Storage: -20°C lyophilized

Research Applications

Dual incretin pathway research
Metabolic and glycemic regulation studies
Body composition research models
Cardiovascular metabolic research
GIP vs GLP-1 mechanism comparison studies

Frequently Asked Questions

What makes tirzepatide different from semaglutide?

What does GIP stand for?

Is tirzepatide a high-demand research compound?

Stock Tirzepatide on Your Research Compound Store

PeptiCommerce provides turn-key access to COA-documented research compounds. Your branded WooCommerce store with P2P and crypto payment support, ready in under 72 hours.

Get Started →

Key Facts

Research Applications

Frequently Asked Questions

Related Terms

Get the Research Peptide Business Playbook